{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T10:33:05Z","timestamp":1758709985176},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2003,2,1]],"date-time":"2003-02-01T00:00:00Z","timestamp":1044057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2003,2]]},"DOI":"10.1053\/sonc.2003.50024","type":"journal-article","created":{"date-parts":[[2005,11,3]],"date-time":"2005-11-03T08:58:14Z","timestamp":1131008294000},"page":"16-20","source":"Crossref","is-referenced-by-count":43,"special_numbering":"S2","title":["Rituximab plus chemotherapy in follicular and mantle cell lymphomas"],"prefix":"10.1053","volume":"30","author":[{"given":"Wolfgang","family":"Hiddemann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Unterhalt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/sonc.2003.50024_BIB1","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/sonc.2003.50024_BIB2","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1200\/JCO.1999.17.6.1851","article-title":"Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab","volume":"17","author":"Davis","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/sonc.2003.50024_BIB3","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment","volume":"18","author":"Davis","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/sonc.2003.50024_BIB4","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s002770000163","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: Results of a phase-II study of the German Low-Grade Lymphoma Study Group","volume":"79","author":"Feuring-Buske","year":"2000","journal-title":"Ann Hematol"},{"issue":"suppl 1","key":"10.1053\/sonc.2003.50024_BIB5","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1007\/s002800100313","article-title":"Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan","volume":"48","author":"Tobinai","year":"2001","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/sonc.2003.50024_BIB6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V97.1.101","article-title":"Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation","volume":"97","author":"Colombat","year":"2001","journal-title":"Blood"},{"issue":"suppl 2","key":"10.1053\/sonc.2003.50024_BIB7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1053\/sonc.2002.30154","article-title":"Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: Interim follow-up of a multicenter phase II trial","volume":"29","author":"Hainsworth","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1053\/sonc.2003.50024_BIB8","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1054\/bjoc.2001.2127","article-title":"Rituximab: Mechanisms and applications","volume":"85","author":"Johnson","year":"2001","journal-title":"Br J Cancer"},{"issue":"suppl 2","key":"10.1053\/sonc.2003.50024_BIB9","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/sonc.2002.30156","article-title":"Rituximab: Mechanism of action and resistance","volume":"29","author":"Maloney","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1053\/sonc.2003.50024_BIB10","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1089\/cbr.1997.12.177","article-title":"Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs","volume":"12","author":"Demidem","year":"1997","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1053\/sonc.2003.50024_BIB11","first-page":"2961","article-title":"Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab","volume":"20","author":"Alas","year":"2000","journal-title":"Anticancer Res"},{"key":"10.1053\/sonc.2003.50024_BIB12","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.1999.17.1.268","article-title":"Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy","volume":"17","author":"Czuczman","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/sonc.2003.50024_BIB13","first-page":"601a","article-title":"Phase II study of rituximab plus fludarabine in patients (pts) with low-grade lymphoma (LGL): Final report","volume":"98","author":"Czuczman","year":"2001","journal-title":"Blood"},{"issue":"suppl 2","key":"10.1053\/sonc.2003.50024_BIB14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1053\/sonc.2002.30152","article-title":"Rituximab in combination with CHOP or fludarabine in low-grade lymphoma","volume":"29","author":"Czuczman","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1053\/sonc.2003.50024_BIB15","first-page":"601a","article-title":"Progression-free survival (PFS) after six years (median) follow-up of the first clinical trial of rituximab\/CHOP immunochemotherapy","volume":"98","author":"Czuczman","year":"2001","journal-title":"Blood"},{"key":"10.1053\/sonc.2003.50024_BIB16","first-page":"844a","volume":"98","author":"Hiddemann","year":"2001","journal-title":"Blood"},{"key":"10.1053\/sonc.2003.50024_BIB17","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.1998.16.5.1922","article-title":"Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: Results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group","volume":"16","author":"Hiddemann","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/sonc.2003.50024_BIB18","first-page":"104","article-title":"B-chronic lymphocytic leukaemia, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma, including Waldenstrom's macroglobulinemia: A clinical, morphologic, and biologic spectrum of similar disorders","volume":"36","author":"Pangalis","year":"1999","journal-title":"Semin Hematol"},{"key":"10.1053\/sonc.2003.50024_BIB19","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.2001.19.2.389","article-title":"Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma","volume":"19","author":"Vose","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/sonc.2003.50024_BIB20","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"suppl 2","key":"10.1053\/sonc.2003.50024_BIB21","first-page":"145","article-title":"Efficacy and toxicity of rituximab plus MCP versus MCP alone in advanced indolent NHL-Interim results of a clinical phase II study of the East German Study Group hematology\/oncology (OSHO)","volume":"13","author":"Herold","year":"2002","journal-title":"Ann Oncol"},{"issue":"suppl 5","key":"10.1053\/sonc.2003.50024_BIB22","first-page":"75","article-title":"Natural history of and therapy for the indolent non-Hodgkin's lymphomas","volume":"20","author":"Horning","year":"1993","journal-title":"Semin Oncol"},{"key":"10.1053\/sonc.2003.50024_BIB23","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","article-title":"The natural history of initially untreated low-grade non-Hodgkin's lymphomas","volume":"311","author":"Horning","year":"1984","journal-title":"N Engl J Med"},{"issue":"suppl 2","key":"10.1053\/sonc.2003.50024_BIB24","first-page":"11","article-title":"The treatment of indolent lymphomas: Watchful waiting v aggressive combined modality treatment","volume":"25","author":"Young","year":"1988","journal-title":"Semin Hematol"},{"key":"10.1053\/sonc.2003.50024_BIB25","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A leukaemia study from the Groupe d'Etude des Lymphomes Folliculaires","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1053\/sonc.2003.50024_BIB26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/hon.2900080105","article-title":"Treatment of low-grade non-Hodgkin's lymphomas: Assessment of doxorubicin in a controlled trial","volume":"8","author":"Lepage","year":"1990","journal-title":"Hematol Oncol"},{"key":"10.1053\/sonc.2003.50024_BIB27","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1200\/JCO.1993.11.4.644","article-title":"Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy","volume":"11","author":"Dana","year":"1993","journal-title":"J Clin Oncol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009377540200026X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009377540200026X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T04:50:04Z","timestamp":1548046204000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009377540200026X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,2]]}},"alternative-id":["S009377540200026X"],"URL":"https:\/\/doi.org\/10.1053\/sonc.2003.50024","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2003,2]]}}}